.png){kind=icon}
.png){kind=icon}
Return
Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for up to 128 Weeks
.png){kind=icon}
PRE
AI
M
Y
K
J
A
Q
S
A
P
N
M
A
D
M
S
K
S
Z
DOI：10.1016/j.jcmg.2025.07.019.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
In the VALOR-HCM (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy; NCT04349072 ) trial, patients with severely symptomatic obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten demonstrated significant improvement in left ventricular outflow tract (LVOT) gradients and echocardiographic indices of cardiac remodeling in the short term.
Journal
IF:
15.2
Papers:
4.3K
Citations:
1.7W
Organization
Cited Papers